Collegium Pharmaceutical, Inc. - Common Stock (COLL)
28.04
-0.40 (-1.41%)
Collegium Pharmaceutical is a biotechnology company that focuses on developing innovative treatments for pain management and related conditions
The company specializes in formulating and bringing to market unique drug delivery systems and therapies that aim to enhance patient outcomes while addressing issues like opioid misuse and dependence. By leveraging advanced technology and scientific research, Collegium strives to provide healthcare professionals and patients with effective and safer alternatives for managing acute and chronic pain, contributing to improving overall quality of life.
Pharmaceutical company Collegium Pharmaceutical (NASDAQCOLL) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 21.5% year on year to $181.9 million. The company expects the full year’s revenue to be around $742.5 million, close to analysts’ estimates. Its non-GAAP profit of $1.77 per share was 15.1% above analysts’ consensus estimates.
COLL stock results show that Collegium Pharmaceutical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
COLL stock results show that Collegium Pharmaceutical beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
U.S. stocks traded lower, with the Nasdaq Composite falling around 150 points on Wednesday. Shares of TDCX Inc. (NYSETDCX) rose sharply during Wednesday’s session after it disclosed receiving a preliminary non-binding acquisition offer.
